<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Chemistry</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/31190889-A152-4789-B093-2ACBCBDE7467"><gtr:id>31190889-A152-4789-B093-2ACBCBDE7467</gtr:id><gtr:firstName>Maya</gtr:firstName><gtr:surname>Thanou</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/694DC185-5F79-4F2B-8824-27C40868F189"><gtr:id>694DC185-5F79-4F2B-8824-27C40868F189</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Miller</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FF003188%2F1"><gtr:id>C8D1082D-41F7-4B55-B2D9-90B2D9915DA8</gtr:id><gtr:title>Enzyme-Triggerable Stealth Release (ETSR) of targeted nanoparticles for cancer gene therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/F003188/1</gtr:grantReference><gtr:abstractText>Targeted drug delivery to disease tissues like tumours is the ultimate therapeutic strategy. If drugs can accumulate in tumour tissue, then unwanted side effects including cellular toxicity can be avoided and therapeutic effects may be improved since both dose and efficacy can increase. In this project our main aim is to harness the potential of nanomedicine by preparing self-assembly, synthetic nanoparticles that carry drugs inside but have and a polymer coating on the outside. However, while the polymer coating is excellent in helping to improve blood-circulation times, local release of encapsulated drugs in or near tumour target cells is heavily impaired. This problem should be soluble by ensuring that the polymer can be released at the required time inside the tumour itself bringing cell death exclusively to tumour cells. Our specific approach is to introduce polymers with peptide sequences that are also substrates for tumour specific enzymes. When such peptide modified nanoparticles reach tumours, those enzymes present should then strip-off the polymer coating revealing core nanoparticles that can easily enter cells and deliver encapsulated drug(s) to local tumour cells. We will construct these nanoparticles by preparing all necessary building blocks chemically and assemble these in such way that peptide sequences will be readily available for the tumour specific enzyme(s). Nucleic acids will used as the first drugs since these can be very specific and are arguably safer than the anticancer cytotoxic agents.</gtr:abstractText><gtr:fund><gtr:end>2010-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2007-11-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>387512</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have identified new methods of nucleic acid drug delivery</gtr:description><gtr:exploitationPathways>there is an ongoing requirement for nucleic acid drug delivery. we have prepared a targeted and specific nanoparticle for cancer for the delivery of siRNA. This can be translated to the clinic</gtr:exploitationPathways><gtr:id>40E590CA-A65A-46D8-84C1-16F8EEA4F3D3</gtr:id><gtr:outcomeId>56d8034e356461.49130098</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2B3696EA-6BD0-4E19-A43A-E478D016CB1D</gtr:id><gtr:title>Examination of the effect of increasing the number of intra-disulfide amino functional groups on the performance of small molecule cyclic polyamine disulfide vectors.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db690c7d80898fcc0140532d26d3c309"><gtr:id>db690c7d80898fcc0140532d26d3c309</gtr:id><gtr:otherNames>Drake CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>56d7f7f88648d0.14947242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9CB10EC-4B73-4197-9C46-3E448D1982B8</gtr:id><gtr:title>Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/737ffe0e530a693d7c0da01892f1528d"><gtr:id>737ffe0e530a693d7c0da01892f1528d</gtr:id><gtr:otherNames>Wang M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>56d7f95a5c4a92.73863613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C997E8BA-3194-4DC0-9AEF-FE9EC00C830B</gtr:id><gtr:title>Enzyme-triggered PEGylated pDNA-nanoparticles for controlled release of pDNA in tumors.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6003593023f8e2e7bcab079098e33009"><gtr:id>6003593023f8e2e7bcab079098e33009</gtr:id><gtr:otherNames>Yingyuad P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>56d7f95693d6e6.73310678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BA4D780-E9D4-49B4-9683-432F57806F6D</gtr:id><gtr:title>DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb71ba5327dc9691d6d48cb048539fd4"><gtr:id>cb71ba5327dc9691d6d48cb048539fd4</gtr:id><gtr:otherNames>M?vel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>doi_53cff8ff8fbe9b9e</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/F003188/1</gtr:identifier></gtr:identifiers><gtr:projectHierarchy><gtr:parents><gtr:parent><gtr:id>C8D1082D-41F7-4B55-B2D9-90B2D9915DA8</gtr:id><gtr:grantRef>EP/F003188/1</gtr:grantRef><gtr:amount>387512.78</gtr:amount><gtr:start>2007-11-12</gtr:start><gtr:end>2010-04-30</gtr:end><gtr:children><gtr:child rel="Transfer"><gtr:id>D8750693-1991-4E50-95EF-D937DD3DFA63</gtr:id><gtr:grantRef>EP/F003188/2</gtr:grantRef><gtr:amount>79804.3</gtr:amount><gtr:start>2010-09-01</gtr:start><gtr:end>2011-07-31</gtr:end><gtr:children/></gtr:child></gtr:children></gtr:parent></gtr:parents></gtr:projectHierarchy><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>E48C802F-8897-4353-910A-09D09331BB82</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Medical science &amp; disease</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>